| Entry |
|
|---|
| Name |
Sitagliptin phosphate (USAN);
Sitagliptin phosphate hydrate (JP17);
Sitagliptin phosphate monohydrate;
Januvia (TN)
|
|---|
| Product |
|
|---|
| Formula |
C16H15F6N5O. H3PO4. H2O
|
|---|
| Exact mass |
523.1055
|
|---|
| Mol weight |
523.3241
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 3969 |
| Product (DG00118): | D06645<JP/US> |
| Product (mixture): | D10261<US> D11064<JP> D11066<US> |
|
|---|
| Efficacy |
Antidiabetic, Dipeptidyl peptidase-4 (DPP-4) inhibitor |
|---|
| Disease |
Type 2 diabetes mellitus [DS: H00409] |
|---|
| Comment |
Mixture of Juvisync (TN)
Treatment of type 2 diabetes mellitus and related disorders
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04974 | Protein digestion and absorption |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH01 Sitagliptin
D06645 Sitagliptin phosphate (USAN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Sitagliptin
D06645 Sitagliptin phosphate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D06645 Sitagliptin phosphate (USAN); Sitagliptin phosphate hydrate (JP17)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Peptidyl-peptidases
DPP4 (CD26)
D06645 Sitagliptin phosphate (USAN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D06645 Sitagliptin phosphate hydrate
D06645 Sitagliptin phosphate tablets
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06645
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06645
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06645
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06645
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 34
1 C8y C 8.1200 -12.2500
2 C8x C 8.1200 -13.6500
3 C8y C 9.3324 -14.3500
4 C8y C 10.5449 -13.6500
5 C8x C 10.5449 -12.2500
6 C8y C 9.3324 -11.5500
7 X F 9.3324 -10.1502
8 X F 9.3324 -15.7498
9 X F 6.9076 -11.5500
10 C1b C 11.7760 -14.3610
11 C1c C 12.9812 -13.6653
12 C1b C 14.1635 -14.3481
13 C5a C 15.3575 -13.6588
14 N1y N 16.5454 -14.3448
15 O5a O 15.3577 -12.2503
16 N1a N 12.9816 -12.2504
17 C1x C 16.5454 -15.7498
18 C1x C 17.7578 -16.4498
19 N4y N 18.9703 -15.7498
20 C8y C 18.9703 -14.3448
21 C1x C 17.7579 -13.6448
22 C8y C 20.3065 -16.1840
23 N5x N 21.1324 -15.0474
24 N5x N 20.3065 -13.9107
25 C1d C 20.3065 -17.5840
26 X F 20.3065 -18.9840
27 X F 21.6999 -17.5839
28 X F 18.9001 -17.5841
29 P1b P 24.7529 -13.5722
30 O1c O 26.0648 -13.5841
31 O1c O 23.5239 -13.5841
32 O1c O 24.8120 -15.0030
33 O1c O 24.7882 -11.9456
34 O0 O 25.6900 -17.7100
BOND 34
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 6 7 1
8 3 8 1
9 1 9 1
10 4 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 13 14 1
15 13 15 2
16 11 16 1 #Up
17 14 17 1
18 17 18 1
19 18 19 1
20 19 20 1
21 20 21 1
22 14 21 1
23 19 22 1
24 22 23 2
25 23 24 1
26 20 24 2
27 22 25 1
28 25 26 1
29 25 27 1
30 25 28 1
31 29 30 1
32 29 31 1
33 29 32 1
34 29 33 2
|
|---|
